Serina Unveils Novel POZ Platform Lipid Nanoparticles
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Should l Buy SER?
Source: Newsfilter
- Novel Lipid Nanoparticles: At the LNP Summit in Boston, Serina Therapeutics showcased novel lipid nanoparticles built on the POZ platform, which did not elicit an antibody response in a vaccine format, indicating potential safety advantages that could disrupt the current LNP formulation market.
- Replacement Strategy Progress: The company is advancing a replacement strategy targeting ionizable lipids, which have raised safety concerns, signaling Serina's ongoing commitment to enhancing the safety of LNP components and potentially boosting its competitive edge in the market.
- Versatile Drug Carriers: The newly designed polymer-lipid can bind a broad range of oligonucleotide payloads, demonstrating versatility and flexibility in drug delivery, which may provide new solutions for treating neurological diseases and expand the company's product pipeline.
- Strategic Partnership Opportunities: Serina intends to advance applications of the POZ platform through out-licensing and co-development, particularly highlighted by its non-exclusive licensing agreement with Pfizer, indicating a strategic positioning in the drug delivery sector that could lay the groundwork for future revenue growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SER?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SER
Wall Street analysts forecast SER stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.050
Low
11.00
Averages
11.00
High
11.00
Current: 2.050
Low
11.00
Averages
11.00
High
11.00
About SER
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Serina Unveils Novel POZ Platform Lipid Nanoparticles
- Novel Lipid Nanoparticles: At the LNP Summit in Boston, Serina Therapeutics showcased novel lipid nanoparticles built on the POZ platform, which did not elicit an antibody response in a vaccine format, indicating potential safety advantages that could disrupt the current LNP formulation market.
- Replacement Strategy Progress: The company is advancing a replacement strategy targeting ionizable lipids, which have raised safety concerns, signaling Serina's ongoing commitment to enhancing the safety of LNP components and potentially boosting its competitive edge in the market.
- Versatile Drug Carriers: The newly designed polymer-lipid can bind a broad range of oligonucleotide payloads, demonstrating versatility and flexibility in drug delivery, which may provide new solutions for treating neurological diseases and expand the company's product pipeline.
- Strategic Partnership Opportunities: Serina intends to advance applications of the POZ platform through out-licensing and co-development, particularly highlighted by its non-exclusive licensing agreement with Pfizer, indicating a strategic positioning in the drug delivery sector that could lay the groundwork for future revenue growth.
See More
Serina Therapeutics Receives NYSE Compliance Plan Approval
- Compliance Plan Approved: Serina Therapeutics' business plan has been accepted by NYSE American LLC, granting the company until July 9, 2027, to regain compliance, demonstrating a proactive approach to regulatory challenges.
- Financial Condition Disclosure: As of December 31, 2024, Serina reported stockholders' equity of $1.6 million and incurred net losses in three of the last four fiscal years, with a net loss of $19.4 million in 2025, highlighting financial pressures and challenges to future profitability.
- Clinical Trial Progress: Serina is advancing its SER-252 clinical program, having enrolled and dosed its first patient in February 2026 for its registrational trial targeting advanced Parkinson's disease, indicating ongoing commitment to research and new therapies.
- Market Performance Analysis: SER stock has traded between $1.22 and $7.92 over the past year, closing at $2.12, with a recent overnight increase of 4.25% to $2.21, reflecting investor interest in the company's future developments.
See More
Serina Therapeutics Receives NYSE Approval to Regain Listing Compliance
- Compliance Plan Approved: Serina Therapeutics (SER) has received NYSE American approval for its plan to regain listing compliance after being flagged on January 9, 2026, due to low equity of $1.6 million and losses in three of the last four years, demonstrating the company's resilience in facing financial challenges.
- Grace Period Established: The company has until July 9, 2027, to meet the listing rules, providing Serina with the necessary time to improve its financial condition and avoid potential delisting risks.
- Quarterly Monitoring Mechanism: During the grace period, NYSE American will monitor Serina quarterly, and failure to meet listing requirements within the cure period may lead to suspension and delisting, which would directly impact shareholder confidence and market performance.
- Funding Opportunities: Serina Therapeutics has also secured up to $30 million in private placement, which will aid in improving its financial situation and support future business development, further enhancing its viability in the capital markets.
See More
Serina Therapeutics Reports FY Earnings and Secures Funding
- Earnings Report: Serina Therapeutics reported a FY GAAP EPS of -$1.91, indicating a loss; however, revenue surged by 116.7% year-over-year to $0.13 million, showcasing the company's growth potential in the market.
- Cash Position: As of December 31, 2025, Serina's cash and cash equivalents totaled $3.1 million, reflecting stability in financial management that supports future operations and R&D efforts.
- Funding Acquisition: The company secured up to $30 million in private placement funding, which will provide essential financial support for subsequent projects and enhance its competitive position in the market.
- Market Outlook: Despite current financial losses, Serina's revenue growth and new funding lay a foundation for future development, potentially attracting more investor interest in its market opportunities.
See More
Serina Receives FDA Clearance for SER-252 Clinical Trial
- FDA Approval for Clinical Trial: In January 2026, Serina received FDA clearance for its IND application for SER-252, marking a significant clinical advancement in treating advanced Parkinson's disease, which is expected to create substantial market opportunities for the company.
- Successful Financing: In March 2026, Serina completed a private placement financing of up to $30 million, securing an initial $15 million with potential for an additional $15 million, providing robust financial support for future clinical milestones.
- Increased R&D Spending: In 2025, Serina's research and development expenses reached $13.2 million, a significant increase from $7.5 million in 2024, primarily driven by clinical activities and headcount growth, demonstrating the company's commitment to advancing its product pipeline.
- Widening Net Loss: In 2025, Serina reported a net loss of $19.4 million, up from $11.1 million in 2024, highlighting the need for cost control measures as the company ramps up its R&D investments while striving for sustainable growth.
See More
Serina Therapeutics Secures $30 Million Financing for Parkinson's Trial
- Financing Amount: Serina Therapeutics has secured up to $30 million through definitive agreements for a private placement to support its registrational trial of SER-252 in advanced Parkinson's disease, indicating a proactive approach in its R&D efforts.
- Phased Financing: The first tranche of $15 million is expected to close on March 20, 2026, with a second tranche of up to $15 million anticipated by April 30, 2026, ensuring liquidity for the company over the next two years.
- Warrant Coverage: The financing includes 50% warrant coverage priced at $5 per share, significantly above market price, and if fully exercised, could provide an additional $33.3 million, extending Serina's cash runway into the second half of 2027.
- Clinical Trial Progress: The single-ascending dose registrational study of SER-252 has commenced with the first patient dosed, and FDA feedback has confirmed a clear regulatory pathway, positioning the financing to help Serina achieve key milestones.
See More
Serina Unveils Novel POZ Platform Lipid Nanoparticles
- Novel Lipid Nanoparticles: At the LNP Summit in Boston, Serina Therapeutics showcased novel lipid nanoparticles built on the POZ platform, which did not elicit an antibody response in a vaccine format, indicating potential safety advantages that could disrupt the current LNP formulation market.
- Replacement Strategy Progress: The company is advancing a replacement strategy targeting ionizable lipids, which have raised safety concerns, signaling Serina's ongoing commitment to enhancing the safety of LNP components and potentially boosting its competitive edge in the market.
- Versatile Drug Carriers: The newly designed polymer-lipid can bind a broad range of oligonucleotide payloads, demonstrating versatility and flexibility in drug delivery, which may provide new solutions for treating neurological diseases and expand the company's product pipeline.
- Strategic Partnership Opportunities: Serina intends to advance applications of the POZ platform through out-licensing and co-development, particularly highlighted by its non-exclusive licensing agreement with Pfizer, indicating a strategic positioning in the drug delivery sector that could lay the groundwork for future revenue growth.
See More
Serina Therapeutics Receives NYSE Compliance Plan Approval
- Compliance Plan Approved: Serina Therapeutics' business plan has been accepted by NYSE American LLC, granting the company until July 9, 2027, to regain compliance, demonstrating a proactive approach to regulatory challenges.
- Financial Condition Disclosure: As of December 31, 2024, Serina reported stockholders' equity of $1.6 million and incurred net losses in three of the last four fiscal years, with a net loss of $19.4 million in 2025, highlighting financial pressures and challenges to future profitability.
- Clinical Trial Progress: Serina is advancing its SER-252 clinical program, having enrolled and dosed its first patient in February 2026 for its registrational trial targeting advanced Parkinson's disease, indicating ongoing commitment to research and new therapies.
- Market Performance Analysis: SER stock has traded between $1.22 and $7.92 over the past year, closing at $2.12, with a recent overnight increase of 4.25% to $2.21, reflecting investor interest in the company's future developments.
See More
Serina Therapeutics Receives NYSE Approval to Regain Listing Compliance
- Compliance Plan Approved: Serina Therapeutics (SER) has received NYSE American approval for its plan to regain listing compliance after being flagged on January 9, 2026, due to low equity of $1.6 million and losses in three of the last four years, demonstrating the company's resilience in facing financial challenges.
- Grace Period Established: The company has until July 9, 2027, to meet the listing rules, providing Serina with the necessary time to improve its financial condition and avoid potential delisting risks.
- Quarterly Monitoring Mechanism: During the grace period, NYSE American will monitor Serina quarterly, and failure to meet listing requirements within the cure period may lead to suspension and delisting, which would directly impact shareholder confidence and market performance.
- Funding Opportunities: Serina Therapeutics has also secured up to $30 million in private placement, which will aid in improving its financial situation and support future business development, further enhancing its viability in the capital markets.
See More
Serina Therapeutics Reports FY Earnings and Secures Funding
- Earnings Report: Serina Therapeutics reported a FY GAAP EPS of -$1.91, indicating a loss; however, revenue surged by 116.7% year-over-year to $0.13 million, showcasing the company's growth potential in the market.
- Cash Position: As of December 31, 2025, Serina's cash and cash equivalents totaled $3.1 million, reflecting stability in financial management that supports future operations and R&D efforts.
- Funding Acquisition: The company secured up to $30 million in private placement funding, which will provide essential financial support for subsequent projects and enhance its competitive position in the market.
- Market Outlook: Despite current financial losses, Serina's revenue growth and new funding lay a foundation for future development, potentially attracting more investor interest in its market opportunities.
See More
Serina Receives FDA Clearance for SER-252 Clinical Trial
- FDA Approval for Clinical Trial: In January 2026, Serina received FDA clearance for its IND application for SER-252, marking a significant clinical advancement in treating advanced Parkinson's disease, which is expected to create substantial market opportunities for the company.
- Successful Financing: In March 2026, Serina completed a private placement financing of up to $30 million, securing an initial $15 million with potential for an additional $15 million, providing robust financial support for future clinical milestones.
- Increased R&D Spending: In 2025, Serina's research and development expenses reached $13.2 million, a significant increase from $7.5 million in 2024, primarily driven by clinical activities and headcount growth, demonstrating the company's commitment to advancing its product pipeline.
- Widening Net Loss: In 2025, Serina reported a net loss of $19.4 million, up from $11.1 million in 2024, highlighting the need for cost control measures as the company ramps up its R&D investments while striving for sustainable growth.
See More
Serina Therapeutics Secures $30 Million Financing for Parkinson's Trial
- Financing Amount: Serina Therapeutics has secured up to $30 million through definitive agreements for a private placement to support its registrational trial of SER-252 in advanced Parkinson's disease, indicating a proactive approach in its R&D efforts.
- Phased Financing: The first tranche of $15 million is expected to close on March 20, 2026, with a second tranche of up to $15 million anticipated by April 30, 2026, ensuring liquidity for the company over the next two years.
- Warrant Coverage: The financing includes 50% warrant coverage priced at $5 per share, significantly above market price, and if fully exercised, could provide an additional $33.3 million, extending Serina's cash runway into the second half of 2027.
- Clinical Trial Progress: The single-ascending dose registrational study of SER-252 has commenced with the first patient dosed, and FDA feedback has confirmed a clear regulatory pathway, positioning the financing to help Serina achieve key milestones.
See More
